neuroClues develops a clinical eye-tracking platform for neurological assessment and monitoring. The company focuses on oculomotor biomarkers, using eye-movement patterns to support more objective examination of Parkinsonian syndromes and broader neurological disorders.

The system combines a compact eye-tracking device with AI-supported analysis of high-speed infrared eye-movement recordings. During a short visual task, the platform captures oculomotor data and extracts reproducible biomarkers that can inform diagnosis, disease monitoring, and treatment follow-up.

neuroClues has CE marking as a Class IIa medical device in Europe and is expanding its clinical rollout across neurology practices, hospitals, and research centers. The company is positioned as a clinician-facing diagnostic infrastructure provider for neurological care, with U.S. market entry under preparation.